Proteocyte Receives Support from NRC-IRAP for Straticyte™

Proteocyte Receives Support from NRC-IRAP for Straticyte™ Intellectual Property Development
 

Proteocyte Diagnostics Inc. today announced the completion of a project enhancing the current version of Straticyte™ and opening up new potential applications. This significant advancement has led to additional Intellectual Property and value creation for the Company.

Proteocyte Diagnostics provides a laboratory service, Straticyte™, for early identification of oral lesions likely to progress to cancer. Late detection of oral cancer is widely acknowledged as the  primary reason for the 50% mortality rate for this disease, so early detection is critical.

The National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) initially provided support to Proteocyte Diagnostics to accelerate the automation of Straticyte™ and refine the prediction algorithm for even greater accuracy. This project was completed successfully and resulted in significant intellectual property for which NRC-IRAP has provided support for the patent filing. Straticyte™ is now able to offer greater objectivity and greater accuracy while enabling capacity for increasedvolumes. The project also provided the product development team with technical experience that will allow for the development of further applications for other cancers.

 “We consider these new developments a significant leap forward for Straticyte™,” said Dr. Ken Pritzker, CEO of Proteocyte Diagnostics. “Straticyte™ has evolved into a platform technology, involving several patented biomarkers, each of which can be optimized for specific clinical applications.”

 “We are grateful for NRC-IRAP continuing support in the development of Straticyte™” said John Jordan, CFO of Proteocyte Diagnostics. “The new development further strengthens our value proposition and broadens our market.”

Proteocyte Diagnostics was the highest ranked life science Company at the National Angel Capital Organization (NACO) Most Promising Canadian Start Up of the Year Competition in 2014.

The Proteocyte Diagnostics’ team continues to build awareness and clinical experience for Straticyte™ with key collaborations and is currently available within a pilot test with a select group of Oral Maxillofacial surgeons, and the Oral Pathology group, University of Western Ontario.

If you would like more information about Straticyte™, please contact Proteocyte Diagnostics: info@proteocyte.com.

About Proteocyte Diagnostics www.proteocyte.com
Proteocyte Diagnostics is a Canadian company that has developed a novel prognostic oral precancer laboratory service, Straticyte™ that objectively and accurately detects oral lesions at high risk of transforming to cancer and those that pose low risk. Early diagnosis of high risk lesions permits more effective and less traumatizing treatments. By identifying and treating oral cancer before it happens, clinicians can save lives, healthcare costs are reduced and quality of life of patients is improved. Identifying more accurately low risk pre-cancerous lesions avoids unnecessary surgeries and allows clinicians to monitor patients regularly for peace of mind.